ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA)

Historical Holders from Q2 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
ADMA on Nasdaq
Shares outstanding
236,833,431
Price per share
$18.24
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
218,110,403
Total reported value
$3,198,315,322
% of total 13F portfolios
0.01%
Share change
+7,420,429
Value change
+$70,760,054
Number of holders
357
Price from insider filings
$18.24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% $865,732,260 35,907,601 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 8.9% $389,033,250 21,363,715 The Vanguard Group 30 Jun 2025
Invesco Ltd. 5.4% +12% $310,221,055 +$37,868,347 12,866,904 +14% Invesco Ltd. 31 Mar 2025
STATE STREET CORP 5.1% +6% $221,519,782 +$11,695,913 12,078,505 +5.6% STATE STREET CORPORATION 30 Jun 2025
As of 30 Sep 2025, ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA) has 357 institutional shareholders filing 13F forms. They hold 218,110,403 shares. of 236,833,431 outstanding shares (92%) .

Top 25 institutional shareholders own 66% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 35,631,714 -2.3% 0.01% $522,360,930
VANGUARD GROUP INC 8.9% 20,974,996 -1.8% 0% $307,493,442
STATE STREET CORP 5.7% 13,561,645 +12% 0.01% $198,813,716
Invesco Ltd. 5.3% 12,505,478 -2.4% 0.03% $183,330,309
Sachem Head Capital Management LP 3.8% 8,960,000 3.7% $131,353,600
GEODE CAPITAL MANAGEMENT, LLC 2.5% 5,813,738 -1.7% 0.01% $85,241,510
Nuveen, LLC 2.4% 5,724,145 +2.9% 0.02% $83,915,966
WESTFIELD CAPITAL MANAGEMENT CO LP 2.2% 5,106,802 0.31% $74,865,717
DIMENSIONAL FUND ADVISORS LP 2% 4,798,274 +0.74% 0.02% $70,343,236
AMERICAN CENTURY COMPANIES INC 2% 4,695,923 +1.8% 0.04% $68,842,245
Thrivent Financial for Lutherans 1.7% 4,141,840 +25% 0.12% $60,719,000
Capital Research Global Investors 1.4% 3,253,913 0.01% $47,702,365
GOLDMAN SACHS GROUP INC 1.2% 2,910,807 +60% 0.01% $42,672,430
RENAISSANCE TECHNOLOGIES LLC 1.2% 2,770,442 -12% 0.05% $40,614,680
OBERWEIS ASSET MANAGEMENT INC/ 1.1% 2,712,040 -14% 1.5% $39,758,506
Caligan Partners LP 1.1% 2,636,609 5.4% $38,652,688
B Group, Inc. 1% 2,412,542 +4.1% 34% $35,367,866
NORTHERN TRUST CORP 1% 2,360,780 -3.4% 0% $34,609,035
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1% 2,360,765 -5.6% 0.01% $34,608,815
Ranger Investment Management, L.P. 0.99% 2,340,730 -2.1% 2.4% $34,315,102
AWM Investment Company, Inc. 0.93% 2,200,000 0% 3% $32,252,000
PRICE T ROWE ASSOCIATES INC /MD/ 0.91% 2,155,662 +0.77% 0% $31,603,000
Perpetual Ltd 0.89% 2,119,291 -27% 0.39% $31,068,806
CITADEL ADVISORS LLC 0.89% 2,119,162 0.02% $31,066,915
FRANKLIN RESOURCES INC 0.85% 2,002,290 -26% 0.01% $29,353,571

Institutional Holders of ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 225,091 $4,108,387 +$3,000,401 $18.24 15
2025 Q3 218,110,403 $3,198,315,322 +$70,760,054 $14.66 357
2025 Q2 210,797,270 $3,837,973,056 +$78,904,738 $18.21 367
2025 Q1 205,274,525 $4,072,982,276 +$76,450,592 $19.84 342
2024 Q4 203,746,953 $3,496,535,119 -$114,107,061 $17.15 316
2024 Q3 207,372,865 $4,143,053,602 +$165,315,203 $19.99 300
2024 Q2 181,187,738 $2,025,731,155 +$84,927,207 $11.18 251
2024 Q1 174,472,998 $1,151,565,465 +$38,336,177 $6.60 213
2023 Q4 169,158,841 $764,627,025 -$2,944,733 $4.52 184
2023 Q3 171,151,086 $612,714,569 +$20,026,265 $3.58 188
2023 Q2 165,493,139 $610,610,254 +$2,418,775 $3.69 178
2023 Q1 165,334,603 $547,246,486 +$39,069,063 $3.31 161
2022 Q4 152,691,438 $592,428,828 +$84,016,367 $3.88 160
2022 Q3 129,844,191 $315,525,087 +$25,706,332 $2.43 126
2022 Q2 119,212,509 $236,039,706 +$28,768,170 $1.98 106
2022 Q1 104,891,672 $189,908,374 +$15,200,552 $1.83 101
2021 Q4 97,211,593 $137,058,638 +$69,617,810 $1.41 79
2021 Q3 41,605,720 $47,012,568 -$1,898,278 $1.13 65
2021 Q2 42,881,498 $68,611,517 -$9,321,193 $1.60 77
2021 Q1 48,542,943 $85,432,065 +$4,580,090 $1.76 99
2020 Q4 45,108,342 $87,965,210 -$3,255,262 $1.95 88
2020 Q3 46,229,823 $110,365,108 -$6,638,253 $2.39 89
2020 Q2 48,795,314 $143,056,287 +$1,125,669 $2.93 95
2020 Q1 48,452,749 $139,501,972 +$45,105,921 $2.88 90
2019 Q4 32,462,778 $129,848,396 -$5,342,106 $4.00 74
2019 Q3 37,184,714 $165,464,669 +$10,136,847 $4.45 71
2019 Q2 35,036,040 $135,582,245 +$49,523,348 $3.87 67
2019 Q1 22,292,511 $84,489,596 -$8,434,826 $3.79 54
2018 Q4 24,691,538 $57,976,000 -$3,589,136 $2.39 49
2018 Q3 26,643,107 $165,449,000 +$8,758,819 $6.21 56
2018 Q2 25,531,842 $115,150,787 +$41,337,517 $4.51 53
2018 Q1 16,954,991 $77,991,000 -$211,472 $4.60 34
2017 Q4 17,028,282 $54,659,000 +$27,531,457 $3.21 23
2017 Q3 8,453,450 $26,039,000 -$2,115,756 $3.08 17
2017 Q2 8,911,060 $33,198,000 -$1,175,766 $3.70 19
2017 Q1 9,228,077 $45,033,000 -$611,446 $4.88 17
2016 Q4 9,372,549 $47,987,000 -$550,899 $5.12 17
2016 Q3 9,476,278 $68,659,000 +$188,653 $7.24 18
2016 Q2 9,523,198 $57,439,000 +$6,745,061 $5.95 27
2016 Q1 8,389,293 $67,868,000 -$263,290 $8.09 21
2015 Q4 8,422,364 $67,999,000 -$508,297 $8.07 24
2015 Q3 7,050,136 $58,941,000 +$163,431 $8.36 23
2015 Q2 3,421,139 $31,680,000 +$720,804 $9.26 22
2015 Q1 6,949,700 $32,778,360 +$9,198,949 $9.80 18
2014 Q4 2,367,783 $26,447,585 +$14,273,703 $11.17 11
2014 Q3 776,863 $8,002,000 +$1,130,613 $10.30 1
2014 Q2 667,099 $6,504,000 +$6,504,000 $9.75 1